Japanese regulatory authority's perspective on biosimilars - authors' reply.
South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions (SONAR), South Carolina College of Pharmacy, the University of South Carolina, Columbia, USA; WJB Dorn VA Medical Center, Columbia, SC, USA; Hollings Cancer Center, Charleston, SC, USA; Arnold School of Public Health, University of South Carolina, Columbia, SC, USA. Electronic address: bennettc@sccp.sc.edu.
Charles L
CL
Bennett
South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions (SONAR), South Carolina College of Pharmacy, the University of South Carolina, Columbia, USA; Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Brian
B
Chen
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
Terhi
T
Hermanson
South Carolina Center of Economic Excellence for Medication Safety and Efficacy and the Southern Network on Adverse Reactions (SONAR), South Carolina College of Pharmacy, the University of South Carolina, Columbia, USA; WJB Dorn VA Medical Center, Columbia, SC, USA; Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Peter
P
Georgantopoulos
Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Oliver A
OA
Sartor
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000592:standards* / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D059451:Biosimilar Pharmaceuticals